长沙地区部分职业人群正常高值血压与慢性肾脏病、职业心理因素相关研究
|
摘要
第一章长沙地区职业人群正常高值血压的现况研究
目的：通过对长沙地区职业人群进行现况调查,了解正常高值血压的流行现状,探讨多种危险因素与其的相关性,量化评估相关因素对正常高值血压的影响,为高血压防治策略的制定提供依据。
方法：采取分层整群抽样方法,于2011年9月～11月对长沙地区辖区内5204名在职工作人员进行包括问卷调查、体格检查和实验室检测在内的现况调查。研究对象根据诊室血压水平分为正常血压组、正常高值血压组和高血压组。采用单因素方差分析或χ2检验比较各组之间特点,采用多因素logistic回归分析相关危险因素对正常高值血压的影响。
结果：①长沙地区职业人群中正常高值血压患病率为33.17%(男性46.63%、女性14.84%),高血压患病率为22.44%。②正常高值血压组平均年龄及男性、高学历人员、吸烟者、经常饮酒者、高脂饮食者比例均明显高于正常血压组(P<0.001)。其空腹血糖、血尿酸、总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平也均明显高于正常血压组,而高密度脂蛋白胆固醇水平则明显低于正常血压组(P<0.001)。高血压组以上趋势更为明显。③正常高值血压人群中,高值亚组的男性所占比例、体重、腰围、目前吸烟率、总胆固醇、甘油三酯水平均明显高于低值亚组(P<0.001)。④正常高值血压组中,代谢综合征患病率为30.01%。⑤经多因素logistic回归分析,年龄增长、男性、中心性肥胖及高脂饮食与正常高值血压密切相关(P<0.001)。
结论：①长沙地区职业人群正常高值血压患病率较高(33.17%)。②正常高值血压人群代谢综合征患病率为30.01%。③年龄增长、男性、中心性肥胖及高脂饮食是正常高值血压的主要危险因素,提示高血压病一级预防中应重视体重、饮食及运动等生活方式的干预。
第二章长沙地区职业人群中正常高值血压合并慢性肾脏病的现况及前瞻性队列研究
目的：了解长沙地区职业人群中正常高值血压者合并慢性肾脏病的现况及相关危险因素；观察职业人群中正常高值血压向高血压及慢性肾脏病的转归,探讨影响其转归的因素,为预防高血压病、慢性肾脏病提供防治参考。
方法：①现况调查采用整群抽样方法,对2011年3月～5月在中南大学湘雅三医院健康管理中心参加年度健康体检的长沙地区区内企事业单位在职工作人员11274人进行包括问卷调查、体格检查和实验室检测在内的现况调查,慢性肾脏病定义为肾小球滤过率下降和蛋白尿阳性；②选择2006年8月在该健康管理中心进行健康体检符合入选条件的1703人作为观察队列,于2006年8月～2011年12月间对观察队列进行定期随访,观察其1年后血压转归情况及随访5年间慢性肾脏病的发生及其影响因素。采用独立样本T检验、单因素方差分析或χ2检验比较各组之间的特点；采用多因素logistic回归分析了解相关危险因素对正常高值血压者合并慢性肾脏病的影响；用生存分析(Kaplan-Meier法)比较各血压水平分组间慢性肾脏病患病风险的差异,并经Log-rank检验。应用多变量Cox比例风险回归模型,校正相关因素后,分析影响正常高值血压者合并慢性肾脏病的可能危险因素。
结果：①符合慢性肾脏病判定标准的共780例,整体CKD患病率为6.92%(男性10.67%,女性1.77%),其中蛋白尿阳性476例,占4.22%(男性6.26%,女性1.43%),无论是慢性肾脏病患病率或蛋白尿阳性率,男性均显著高于女性。②慢性肾脏病患病率随血压水平分组递增,分别为3.82%、6.93%、11.45%和18.85%。③仅在男性中发现经校正如年龄、肥胖、糖代谢异常、高脂血症、高尿酸血症等因素后,正常高值血压明显增加慢性肾脏病患病风险(OR：1.29595%CI：1.030～1.627,P<0.05)。④高尿酸血症是男性正常高值血压者合并慢性肾脏病的独立危险因素(OR：2.25295%CI：1.592-3.186,P<0.05)。⑤前瞻性队列研究中正常高值血压组1年后有110例进展至高血压(转归率30.77%),168例转归为正常血压(转归率20.15%)。影响其血压转归的因素包括性别、基线血压水平及有无危险因素聚集(代谢综合征)。⑥在平均54个月随访期间,有194例检出患慢性肾脏病,其中131例仅为eGFR<60mL/min/1.73m2,占67.53%；42例仅为蛋白尿阳性,占21.65%；二者兼存在的有19例,占10.82%。⑦经Kaplan-Meier法分析,不同血压分组间CKD的累积发病率有明显差异(P<0.001)。⑧经COX比例风险模型进行逐步回归分析,结果显示影响CKD发病风险的因素包括年龄、估算肾小球滤过率、收缩压和舒张压。
结论：①长沙地区职业人群中整体CKD患病率为6.92%(男性10.67%,女性1.77%),在正常高值血压组中患病率为6.93%,显著高于正常血压组(P<0.001)；②男性经校正相关因素后,正常高值血压明显增加慢性肾脏病患病风险；③高尿酸血症是男性正常高值血压者合并慢性肾脏病的独立危险因素；④正常高值血压及高血压可显著增加患慢性肾脏病的风险；⑤影响慢性肾脏病发病风险的主要因素包括年龄、性别、估算肾小球滤过率、收缩压和舒张压。
第三章以脑力劳动为主职业人群隐匿性高血压的特点及与职业紧张关系的研究
目的：了解本地区以脑力劳动为主职业人群中隐匿性高血压患者的特点及靶器官损害情况；探讨隐匿性高血压与职业紧张的关系。
方法：2011年4月～2012年3月采用方便抽样方法,调查对象来自长沙地区区内四个机关事业单位在职工作人员,其中选取符合入选标准的375人作为调查对象。调查方法主要有①通过诊室血压测量及动态血压测量诊断隐匿性高血压；②通过左室重量指数(LVMI)、颈动脉内中膜厚度(carotid IMT)测定评估其靶器官损害；③通过职业紧张问卷(中文版Karasek工作内容问卷JCQ)评估其职业紧张程度。计量资料检验采用t检验,计数资料采用χ2检验,运用χ2检验比较各组社会人口学特征、个体行为特征；运用协方差分析,校正相关因素后比较各组靶器官损害情况；运用二分类logistic回归分析、多因素logistic回归分析各变量与隐匿性高血压患病率关系。P<0.05说明差异有统计学意义,P<0.01说明有显著性差异。
结果：①在正常血压组中检出10例(4.6%)隐匿性高血压,而在正常高值血压组中检出36例(22.6%)。②隐匿性高血压患者颈动脉IMT、LVMI、均高于血压正常组(P<0.001),且其中诊室正常高值血压亚组的隐匿性高血压患者心血管重构更为明显。③隐匿性高血压在被动型中患病率较高(32.6%),而在放松型中患病率较低(17.4%)。④高工作需求为隐匿性高血压独立的危险因素(OR：1.84；95%CI：1.45-2.32)；另外男性、肥胖、经常吸烟和经常饮酒也是隐匿性高血压的危险因素。⑤男性职业紧张类型中主动型与隐匿性高血压有相关性(OR：2.04；95%CI：1.17-3.58),而女性未见各职业紧张类型与隐匿性高血压有明显相关性。
结论：①隐匿性高血压患者较正常血压者靶器官损害程度有一定增加,鉴于其在诊室正常高值血压者中患病率较高,临床上应重视对诊室正常高值血压人群,特别是已携带心血管危险因素者进行隐匿性高血压的风险筛查。②职业人群中男性且体型肥胖、同时生活方式不良者患隐匿性高血压的风险较高,临床上应关注这类人群并进行职业卫生健康宣教中普及隐匿性高血压知识及家庭自测血压方法。
第四章基于PDCA循环管理的对功能社区正常高值血压人群健康教育效果评价
目的：在功能社区中对正常高值血压人群实施PDCA循环管理模式构建的健康教育计划,探讨其在实施高血压健康教育中的效果,为促进和完善包括高血压在内的慢性病健康教育策略提供实证依据。
方法：采用整群配对随机对照设计,选取2010年4月～6月在中南大学湘雅三医院健康管理中心参加年度健康体检的长沙地区区内在职工作人员中正常高值血压者5585人作为调查对象。采用基于PDCA循环管理模式构建的健康教育计划对试验组进行为期2年的生活方式干预,同期对照组进行常规电话随访。两组间各次访视时各监测指标的变化值比较采用T检验,并进一步用协方差分析对降压效果(两组的净差值)进行调整；用χ2检验进行分类资料的组间比较。
结果：①干预组在2年后收缩压平均水平净下降1.76mmHg,舒张压平均水平净下降6.31mmHg。同时2年后两组间血压转化率有显著性差异,干预组有20.28%转变为正常血压,明显高于对照组的15.59%；而且干预组较对照组高血压转化率降低了近10%。②干预组在2年后很少运动的人员比例明显低于对照组(P<0.05),而纵向比较其常吸烟、很少运动的人数也在减少；类似变化也出现于对照组,其常吸烟、很少运动的人员比例也低于基线水平(P<0.05)。③干预组2年后除空腹血糖外,其余各指标均较基线时有明显改善(P<0.05),而且其多数指标也较对照组有一定程度改善,组间总胆固醇和空腹血糖水平有显著性差异(P<0.05)。
结论：基于PDCA循环管理的健康教育模式是一种良好的预防高血压生活方式干预模式；疾病预防与控制相关部门与功能社区紧密合作,对正常高值血压职业人群实施有序、有质健康教育,是预防职业人群高血压及其并发症的有效措施,值得推广应用。
PART1Prevalence of high-normal blood pressure and associated risk factors among the occupational population in Changsha
Objective:As the pace of life of China speeds up, most of China's elite workforce lead unhealthy lives, obesity and high-blood pressure occur at an earlier age. So it is important to estimate the prevalence of high-normal blood pressure and identify risk factors in the populations.
Methods:Using a stratified cluster sampling method, a representative sample of5,204white collar workers aged20～60years in Changsha was selected between September2011and November2011. Anthropometry, blood pressure, and blood sample were measured with standard instruments and methodology for all the study subjects. Multiple logistic regression methods were used to identify risk factors for high-blood pressure.
Results:The prevalence of high-blood pressure and hypertension was33.17%and22.44%, respectively, in all participants. It was higher in males (46.63%) than females (14.84%) for high-blood pressure. Multiple logistic regression showed that middle age (adjusted odds ratio [OR]=1.37,95%confidence interval [CI]:1.01-1.86), male sex (OR=13.40,95%CI:10.93-16.44), central obesity (OR=2.51,95%CI:2.15-2.93), and eating fried food (OR=1.22,95%CI:1.00-1.48) were risk factors for high-blood pressure.
Conclusion:High-blood pressure is common among relatively young and apparently healthy white collar workers in urban China, and cardiovascular risk factors cluster during high-blood pressure. It is an important public health challenge that adopts appropriate interventions to prehypertensive occupational groups in different degrees effectively.
PART2High-normal blood pressure, hyperuricemia, and risk of chronic kidney disease among the occupational population in Changsha
Objective:To investigate the relationship between high-normal blood pressure and chronic kidney disease (CKD) in a middle-aged occupational population in Changsha. Furthermore, is to evaluate whether high-normal blood pressure is related to the incidence of CKD during the six-year follow-up.
Methods:①Using a cluster sampling method, a cross-sectional survey of representative sample of11274white collar workers was carried out in Changsha between March2011and May2011. Chronic kidney disease was defined as eGFR less than60mL/min per1-73m2or the presence of proteinuria. Anthropometry, blood pressure, blood sample and urine sample were measured with standard instruments and methodology for all the study subjects. Multiple logistic regression methods were used to identify risk factors for CKD.②A prospective cohort study was carried out in1703white collar workers without pre-existing CKD in Changsha in2006at baseline. The cohort population was followed for an average of54months by annual examinations. Kaplan-Meier estimates were calculated for CKD. The association of blood pressure, serum uric acid and CKD incidence was examined using a Cox regression model adjusted for relevant factors.
Results:①The prevalence of CKD among those with high-normal blood pressure and undiagnosed hypertension were6.93%and11.45%, respectively, compared with18.85%with diagnosed hypertension and3.82%with normal blood pressure, and10.67%in men, and1.77%in women, with a significant difference between genders at each strata of blood pressure.②In men, but not in women, whose blood pressure was high-normal blood pressure, the CKD risk was significantly greater (0R=1.30,95%CI:1.03～1.63) than those with optimal blood pressure.③Hyperuricemia was significantly associated with an increased risk of CKD in men, but not in women (OR=1.79,95%CI:1.48～2.16), and there was an additive effect of hyperuricemia and high-normal blood pressure on CKD risk in men compared with men with optimal blood pressure.④There were3664high-normal blood pressure subjects during the first visit and110subjects developed hypertension during the second visit (30.77%) and multiple logistic regression analysis showed that gender(male), blood pressure at baseline, metabolic syndrome were the risk factors of blood pressure progression.⑤During the follow-up of cohort,194incidences of CKD were recorded. Kaplan-Meier curves showed there was a significant difference in the cumulative incidence of CKD between the different blood pressure categories (log-rank test, P<0.001).⑥The independent risk factors of CKD were age, eGFR, systolic blood pressure,and diastolic blood pressure according to the COX proportional hazard analysis.
Conclusion:High-normal blood pressure, as well as hypertension, is significantly associated with CKD among occupational population in Changsha. High-normal blood pressure, particularly in conjunction with hyperuricemia, was found to be an independent risk factor of CKD in men. The results indicate that active control of the blood pressure of high-normal blood pressure individuals is needed to prevent deterioration of kidney function.
PART3Characteristics of masked hypertension in normotensive and white collar workers with high-blood pressure and the association between masked hypertension and job strain
Objective:To identify demographic, lifestyle, clinical and psychological characteristics of masked hypertension in occupational population in Changsha. Furthermore, is to evaluate whether job strain is associated with the prevalence of masked hypertension.
Methods:Study population was drawn from the participants of four public institutions in Changsha between April2011and March2012. There were375white collar workers with normotensive or high-blood pressure underwent office and ambulatory blood pressure measurements, risk factors and target organ damage were evaluated as well. The Chinese version of Karasek's Job Content Questionnaire (C-JCQ) was used to measure job strain. Masked hypertension was defined as normal office blood pressure (<140/90mm Hg) with elevated ambulatory blood pressure (≥135/85mmHg)
Results:①The prevalence of masked hypertension among those with normotensive and high-normal blood pressure were4.6%and22.6%, respectively.②The carotid intima-media thickness and left ventricular mass index tended to increase from true normotensive through masked hypertension with normal office blood pressure to masked hypertension with high-normal office blood pressure.③In men, but not in women, being in the active group (high psychological demands and high decision latitude) was associated with MH (OR:2.04;95%CI:1.17～3.58)
Conclusion:The prevalence of masked hypertension was high in the high-normal office blood pressure compared with those normotensives. The cardiovascular risk profile of masked hypertension was increased as well. Masked hypertension is associated with job strain in men and workers in "active" job situations may be more vulnerable to have hypertension.
PART4Effect of follow-up management based on PDCA circulation in occupational population with high-blood pressure
Objective:To evaluate the effect of follow-up management based on PDCA circulation in promoting lifestyle modification among occupational population with high-blood pressure.
Methods:A parallel study base on a cluster-paired randomized trial was carried out in5585staff from36enterprises and public institutions of Changsha between April2010and March2012. The experimental group received the PDCA-based lifestyle intervention while the control group received the conventional follow-up conducted by doctors and nurse of the health management center.
Results:After two-year intervention, the mean systolic blood pressure and diastolic blood pressure of the intervention group incrementally decreased by1.76mmHg and6.13mm Hg, respectively. Meanwhile, the progression is postponed from high-blood pressure to hypertension, which the rate of prognosis decreased by nearly10%. The intervention group had better behavior prevalence than the control group including quitting smoking and more frequent aerobic exercise (P<0.05).Most of the biochemical indexes in the experimental group were significantly better than those of control group as well (P<0.05)
Conclusion:The follow-up management based on PDCA circulation is an interactive and flexible model, which resulted in improvement of the participants'blood pressure control and lifestyle.
目的：通过对长沙地区职业人群进行现况调查,了解正常高值血压的流行现状,探讨多种危险因素与其的相关性,量化评估相关因素对正常高值血压的影响,为高血压防治策略的制定提供依据。
方法：采取分层整群抽样方法,于2011年9月～11月对长沙地区辖区内5204名在职工作人员进行包括问卷调查、体格检查和实验室检测在内的现况调查。研究对象根据诊室血压水平分为正常血压组、正常高值血压组和高血压组。采用单因素方差分析或χ2检验比较各组之间特点,采用多因素logistic回归分析相关危险因素对正常高值血压的影响。
结果：①长沙地区职业人群中正常高值血压患病率为33.17%(男性46.63%、女性14.84%),高血压患病率为22.44%。②正常高值血压组平均年龄及男性、高学历人员、吸烟者、经常饮酒者、高脂饮食者比例均明显高于正常血压组(P<0.001)。其空腹血糖、血尿酸、总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平也均明显高于正常血压组,而高密度脂蛋白胆固醇水平则明显低于正常血压组(P<0.001)。高血压组以上趋势更为明显。③正常高值血压人群中,高值亚组的男性所占比例、体重、腰围、目前吸烟率、总胆固醇、甘油三酯水平均明显高于低值亚组(P<0.001)。④正常高值血压组中,代谢综合征患病率为30.01%。⑤经多因素logistic回归分析,年龄增长、男性、中心性肥胖及高脂饮食与正常高值血压密切相关(P<0.001)。
结论：①长沙地区职业人群正常高值血压患病率较高(33.17%)。②正常高值血压人群代谢综合征患病率为30.01%。③年龄增长、男性、中心性肥胖及高脂饮食是正常高值血压的主要危险因素,提示高血压病一级预防中应重视体重、饮食及运动等生活方式的干预。
第二章长沙地区职业人群中正常高值血压合并慢性肾脏病的现况及前瞻性队列研究
目的：了解长沙地区职业人群中正常高值血压者合并慢性肾脏病的现况及相关危险因素；观察职业人群中正常高值血压向高血压及慢性肾脏病的转归,探讨影响其转归的因素,为预防高血压病、慢性肾脏病提供防治参考。
方法：①现况调查采用整群抽样方法,对2011年3月～5月在中南大学湘雅三医院健康管理中心参加年度健康体检的长沙地区区内企事业单位在职工作人员11274人进行包括问卷调查、体格检查和实验室检测在内的现况调查,慢性肾脏病定义为肾小球滤过率下降和蛋白尿阳性；②选择2006年8月在该健康管理中心进行健康体检符合入选条件的1703人作为观察队列,于2006年8月～2011年12月间对观察队列进行定期随访,观察其1年后血压转归情况及随访5年间慢性肾脏病的发生及其影响因素。采用独立样本T检验、单因素方差分析或χ2检验比较各组之间的特点；采用多因素logistic回归分析了解相关危险因素对正常高值血压者合并慢性肾脏病的影响；用生存分析(Kaplan-Meier法)比较各血压水平分组间慢性肾脏病患病风险的差异,并经Log-rank检验。应用多变量Cox比例风险回归模型,校正相关因素后,分析影响正常高值血压者合并慢性肾脏病的可能危险因素。
结果：①符合慢性肾脏病判定标准的共780例,整体CKD患病率为6.92%(男性10.67%,女性1.77%),其中蛋白尿阳性476例,占4.22%(男性6.26%,女性1.43%),无论是慢性肾脏病患病率或蛋白尿阳性率,男性均显著高于女性。②慢性肾脏病患病率随血压水平分组递增,分别为3.82%、6.93%、11.45%和18.85%。③仅在男性中发现经校正如年龄、肥胖、糖代谢异常、高脂血症、高尿酸血症等因素后,正常高值血压明显增加慢性肾脏病患病风险(OR：1.29595%CI：1.030～1.627,P<0.05)。④高尿酸血症是男性正常高值血压者合并慢性肾脏病的独立危险因素(OR：2.25295%CI：1.592-3.186,P<0.05)。⑤前瞻性队列研究中正常高值血压组1年后有110例进展至高血压(转归率30.77%),168例转归为正常血压(转归率20.15%)。影响其血压转归的因素包括性别、基线血压水平及有无危险因素聚集(代谢综合征)。⑥在平均54个月随访期间,有194例检出患慢性肾脏病,其中131例仅为eGFR<60mL/min/1.73m2,占67.53%；42例仅为蛋白尿阳性,占21.65%；二者兼存在的有19例,占10.82%。⑦经Kaplan-Meier法分析,不同血压分组间CKD的累积发病率有明显差异(P<0.001)。⑧经COX比例风险模型进行逐步回归分析,结果显示影响CKD发病风险的因素包括年龄、估算肾小球滤过率、收缩压和舒张压。
结论：①长沙地区职业人群中整体CKD患病率为6.92%(男性10.67%,女性1.77%),在正常高值血压组中患病率为6.93%,显著高于正常血压组(P<0.001)；②男性经校正相关因素后,正常高值血压明显增加慢性肾脏病患病风险；③高尿酸血症是男性正常高值血压者合并慢性肾脏病的独立危险因素；④正常高值血压及高血压可显著增加患慢性肾脏病的风险；⑤影响慢性肾脏病发病风险的主要因素包括年龄、性别、估算肾小球滤过率、收缩压和舒张压。
第三章以脑力劳动为主职业人群隐匿性高血压的特点及与职业紧张关系的研究
目的：了解本地区以脑力劳动为主职业人群中隐匿性高血压患者的特点及靶器官损害情况；探讨隐匿性高血压与职业紧张的关系。
方法：2011年4月～2012年3月采用方便抽样方法,调查对象来自长沙地区区内四个机关事业单位在职工作人员,其中选取符合入选标准的375人作为调查对象。调查方法主要有①通过诊室血压测量及动态血压测量诊断隐匿性高血压；②通过左室重量指数(LVMI)、颈动脉内中膜厚度(carotid IMT)测定评估其靶器官损害；③通过职业紧张问卷(中文版Karasek工作内容问卷JCQ)评估其职业紧张程度。计量资料检验采用t检验,计数资料采用χ2检验,运用χ2检验比较各组社会人口学特征、个体行为特征；运用协方差分析,校正相关因素后比较各组靶器官损害情况；运用二分类logistic回归分析、多因素logistic回归分析各变量与隐匿性高血压患病率关系。P<0.05说明差异有统计学意义,P<0.01说明有显著性差异。
结果：①在正常血压组中检出10例(4.6%)隐匿性高血压,而在正常高值血压组中检出36例(22.6%)。②隐匿性高血压患者颈动脉IMT、LVMI、均高于血压正常组(P<0.001),且其中诊室正常高值血压亚组的隐匿性高血压患者心血管重构更为明显。③隐匿性高血压在被动型中患病率较高(32.6%),而在放松型中患病率较低(17.4%)。④高工作需求为隐匿性高血压独立的危险因素(OR：1.84；95%CI：1.45-2.32)；另外男性、肥胖、经常吸烟和经常饮酒也是隐匿性高血压的危险因素。⑤男性职业紧张类型中主动型与隐匿性高血压有相关性(OR：2.04；95%CI：1.17-3.58),而女性未见各职业紧张类型与隐匿性高血压有明显相关性。
结论：①隐匿性高血压患者较正常血压者靶器官损害程度有一定增加,鉴于其在诊室正常高值血压者中患病率较高,临床上应重视对诊室正常高值血压人群,特别是已携带心血管危险因素者进行隐匿性高血压的风险筛查。②职业人群中男性且体型肥胖、同时生活方式不良者患隐匿性高血压的风险较高,临床上应关注这类人群并进行职业卫生健康宣教中普及隐匿性高血压知识及家庭自测血压方法。
第四章基于PDCA循环管理的对功能社区正常高值血压人群健康教育效果评价
目的：在功能社区中对正常高值血压人群实施PDCA循环管理模式构建的健康教育计划,探讨其在实施高血压健康教育中的效果,为促进和完善包括高血压在内的慢性病健康教育策略提供实证依据。
方法：采用整群配对随机对照设计,选取2010年4月～6月在中南大学湘雅三医院健康管理中心参加年度健康体检的长沙地区区内在职工作人员中正常高值血压者5585人作为调查对象。采用基于PDCA循环管理模式构建的健康教育计划对试验组进行为期2年的生活方式干预,同期对照组进行常规电话随访。两组间各次访视时各监测指标的变化值比较采用T检验,并进一步用协方差分析对降压效果(两组的净差值)进行调整；用χ2检验进行分类资料的组间比较。
结果：①干预组在2年后收缩压平均水平净下降1.76mmHg,舒张压平均水平净下降6.31mmHg。同时2年后两组间血压转化率有显著性差异,干预组有20.28%转变为正常血压,明显高于对照组的15.59%；而且干预组较对照组高血压转化率降低了近10%。②干预组在2年后很少运动的人员比例明显低于对照组(P<0.05),而纵向比较其常吸烟、很少运动的人数也在减少；类似变化也出现于对照组,其常吸烟、很少运动的人员比例也低于基线水平(P<0.05)。③干预组2年后除空腹血糖外,其余各指标均较基线时有明显改善(P<0.05),而且其多数指标也较对照组有一定程度改善,组间总胆固醇和空腹血糖水平有显著性差异(P<0.05)。
结论：基于PDCA循环管理的健康教育模式是一种良好的预防高血压生活方式干预模式；疾病预防与控制相关部门与功能社区紧密合作,对正常高值血压职业人群实施有序、有质健康教育,是预防职业人群高血压及其并发症的有效措施,值得推广应用。
PART1Prevalence of high-normal blood pressure and associated risk factors among the occupational population in Changsha
Objective:As the pace of life of China speeds up, most of China's elite workforce lead unhealthy lives, obesity and high-blood pressure occur at an earlier age. So it is important to estimate the prevalence of high-normal blood pressure and identify risk factors in the populations.
Methods:Using a stratified cluster sampling method, a representative sample of5,204white collar workers aged20～60years in Changsha was selected between September2011and November2011. Anthropometry, blood pressure, and blood sample were measured with standard instruments and methodology for all the study subjects. Multiple logistic regression methods were used to identify risk factors for high-blood pressure.
Results:The prevalence of high-blood pressure and hypertension was33.17%and22.44%, respectively, in all participants. It was higher in males (46.63%) than females (14.84%) for high-blood pressure. Multiple logistic regression showed that middle age (adjusted odds ratio [OR]=1.37,95%confidence interval [CI]:1.01-1.86), male sex (OR=13.40,95%CI:10.93-16.44), central obesity (OR=2.51,95%CI:2.15-2.93), and eating fried food (OR=1.22,95%CI:1.00-1.48) were risk factors for high-blood pressure.
Conclusion:High-blood pressure is common among relatively young and apparently healthy white collar workers in urban China, and cardiovascular risk factors cluster during high-blood pressure. It is an important public health challenge that adopts appropriate interventions to prehypertensive occupational groups in different degrees effectively.
PART2High-normal blood pressure, hyperuricemia, and risk of chronic kidney disease among the occupational population in Changsha
Objective:To investigate the relationship between high-normal blood pressure and chronic kidney disease (CKD) in a middle-aged occupational population in Changsha. Furthermore, is to evaluate whether high-normal blood pressure is related to the incidence of CKD during the six-year follow-up.
Methods:①Using a cluster sampling method, a cross-sectional survey of representative sample of11274white collar workers was carried out in Changsha between March2011and May2011. Chronic kidney disease was defined as eGFR less than60mL/min per1-73m2or the presence of proteinuria. Anthropometry, blood pressure, blood sample and urine sample were measured with standard instruments and methodology for all the study subjects. Multiple logistic regression methods were used to identify risk factors for CKD.②A prospective cohort study was carried out in1703white collar workers without pre-existing CKD in Changsha in2006at baseline. The cohort population was followed for an average of54months by annual examinations. Kaplan-Meier estimates were calculated for CKD. The association of blood pressure, serum uric acid and CKD incidence was examined using a Cox regression model adjusted for relevant factors.
Results:①The prevalence of CKD among those with high-normal blood pressure and undiagnosed hypertension were6.93%and11.45%, respectively, compared with18.85%with diagnosed hypertension and3.82%with normal blood pressure, and10.67%in men, and1.77%in women, with a significant difference between genders at each strata of blood pressure.②In men, but not in women, whose blood pressure was high-normal blood pressure, the CKD risk was significantly greater (0R=1.30,95%CI:1.03～1.63) than those with optimal blood pressure.③Hyperuricemia was significantly associated with an increased risk of CKD in men, but not in women (OR=1.79,95%CI:1.48～2.16), and there was an additive effect of hyperuricemia and high-normal blood pressure on CKD risk in men compared with men with optimal blood pressure.④There were3664high-normal blood pressure subjects during the first visit and110subjects developed hypertension during the second visit (30.77%) and multiple logistic regression analysis showed that gender(male), blood pressure at baseline, metabolic syndrome were the risk factors of blood pressure progression.⑤During the follow-up of cohort,194incidences of CKD were recorded. Kaplan-Meier curves showed there was a significant difference in the cumulative incidence of CKD between the different blood pressure categories (log-rank test, P<0.001).⑥The independent risk factors of CKD were age, eGFR, systolic blood pressure,and diastolic blood pressure according to the COX proportional hazard analysis.
Conclusion:High-normal blood pressure, as well as hypertension, is significantly associated with CKD among occupational population in Changsha. High-normal blood pressure, particularly in conjunction with hyperuricemia, was found to be an independent risk factor of CKD in men. The results indicate that active control of the blood pressure of high-normal blood pressure individuals is needed to prevent deterioration of kidney function.
PART3Characteristics of masked hypertension in normotensive and white collar workers with high-blood pressure and the association between masked hypertension and job strain
Objective:To identify demographic, lifestyle, clinical and psychological characteristics of masked hypertension in occupational population in Changsha. Furthermore, is to evaluate whether job strain is associated with the prevalence of masked hypertension.
Methods:Study population was drawn from the participants of four public institutions in Changsha between April2011and March2012. There were375white collar workers with normotensive or high-blood pressure underwent office and ambulatory blood pressure measurements, risk factors and target organ damage were evaluated as well. The Chinese version of Karasek's Job Content Questionnaire (C-JCQ) was used to measure job strain. Masked hypertension was defined as normal office blood pressure (<140/90mm Hg) with elevated ambulatory blood pressure (≥135/85mmHg)
Results:①The prevalence of masked hypertension among those with normotensive and high-normal blood pressure were4.6%and22.6%, respectively.②The carotid intima-media thickness and left ventricular mass index tended to increase from true normotensive through masked hypertension with normal office blood pressure to masked hypertension with high-normal office blood pressure.③In men, but not in women, being in the active group (high psychological demands and high decision latitude) was associated with MH (OR:2.04;95%CI:1.17～3.58)
Conclusion:The prevalence of masked hypertension was high in the high-normal office blood pressure compared with those normotensives. The cardiovascular risk profile of masked hypertension was increased as well. Masked hypertension is associated with job strain in men and workers in "active" job situations may be more vulnerable to have hypertension.
PART4Effect of follow-up management based on PDCA circulation in occupational population with high-blood pressure
Objective:To evaluate the effect of follow-up management based on PDCA circulation in promoting lifestyle modification among occupational population with high-blood pressure.
Methods:A parallel study base on a cluster-paired randomized trial was carried out in5585staff from36enterprises and public institutions of Changsha between April2010and March2012. The experimental group received the PDCA-based lifestyle intervention while the control group received the conventional follow-up conducted by doctors and nurse of the health management center.
Results:After two-year intervention, the mean systolic blood pressure and diastolic blood pressure of the intervention group incrementally decreased by1.76mmHg and6.13mm Hg, respectively. Meanwhile, the progression is postponed from high-blood pressure to hypertension, which the rate of prognosis decreased by nearly10%. The intervention group had better behavior prevalence than the control group including quitting smoking and more frequent aerobic exercise (P<0.05).Most of the biochemical indexes in the experimental group were significantly better than those of control group as well (P<0.05)
Conclusion:The follow-up management based on PDCA circulation is an interactive and flexible model, which resulted in improvement of the participants'blood pressure control and lifestyle.
引文
[1]顾东风,Jiang He,吴锡桂等.中国成年人主要死亡原因及其危险因素,中国慢性病预防与控制,(2006)149-154.
[2]A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, Jr., E.J. Roccella, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report, JAMA:the journal of the American Medical Association,289 (2003) 2560-2572.
[3]刘力生.2004年中国高血压防治指南(实用本),中华心血管病杂志,(2004)9-13.
[4]刘力生.中国高血压防治指南2010,中华高血压杂志,19(2011)701-743.
[5]A.I. Qureshi, M.F. Suri, J.F. Kirmani, A.A. Divani, Prevalence and trends of prehypertension and hypertension in United States:National Health and Nutrition Examination Surveys 1976 to 2000, Medical science monitor international medical journal of experimental and clinical research,11 (2005) CR403-409.
[6]李立明,饶克勤,孔灵芝等.中国居民营养与健康状况调查技术执行组,中国居民2002年营养与健康状况调查,中华流行病学杂志,(2005)478-484.
[7]胡世莲,吴蕾,方向等.安徽省中部地区职业人群正常高值血压状况及危险因素分析,中国慢性病预防与控制,107(2010)223-225.
[8]王薇,赵冬,孙佳艺等.中国正常高值血压人群的心血管病发病危险,中华高血压杂志,96(2007)984-987.
[9]李巧先,张春梅.包头钢铁公司职工高血压患病及血压分布现状,中国慢性病预防与控制,93(2008)87-88.
[10]唐晓鸿,袁洪,曾丽雄等.长沙地区公务员正常高值血压、高血压流行现状及危险因素分析,中国动脉硬化杂志,102(2009)409-413.
[11]E. Manios, G. Tsivgoulis, E. Koroboki, K. Stamatelopoulos, C. Papamichael, S. Toumanidis, E. Stamboulis, K. Vemmos, N. Zakopoulos, Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass, Stroke,40 (2009) 1515-1518.
[12]M.J. Pletcher, K. Bibbins-Domingo, C.E. Lewis, G.S. Wei, S. Sidney, J.J. Carr, E. Vittinghoff, C.E. McCulloch, S.B. Hulley, Prehypertension during young adulthood and coronary calcium later in life, Ann Intern Med,149 (2008) 91-99.
[13]B.R. Weil, B.L. Stauffer, J.J. Greiner, C.A. DeSouza, Prehypertension is associated with impaired nitric oxide-mediated endothelium-dependent vasodilation in sedentary adults, Am J Hypertens,24 (2011) 976-981.
[14]M.R. Markus, J. Stritzke, W. Lieb, B. Mayer, A. Luchner, A. Doring, U. Keil, H.W. Hense, H. Schunkert, Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function:the MONICA/KORA Augsburg study, J Hypertens,26 (2008) 2040-2049.
[15]N.M. Shara, H.E. Resnick, L. Lu, J. Xu, S. Vupputuri, B.V. Howard, J.G Umans, Decreased GFR estimated by MDRD or Cockcroft-Gault equation predicts incident CVD:the strong heart study, Journal of nephrology,22 (2009) 373-380.
[16]A. Kiyosue, Y. Hirata, J. Ando, H. Fujita, T. Morita, M. Takahashi, D. Nagata, T. Kohro, Y. Imai, R. Nagai, Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients, Circulation journal:official journal of the Japanese Circulation Society,74 (2010) 786-791.
[17]F. Wang, P. Ye, L. Luo, W. Xiao, H. Wu, Association of risk factors for cardiovascular disease and glomerular filtration rate:a community-based study of 4,925 adults in Beijing, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,25 (2010) 3924-3931.
[18]L. Zhang, F. Wang, L. Wang, W. Wang, B. Liu, J. Liu, M. Chen, Q. He, Y. Liao, X. Yu, N. Chen, J.E. Zhang, Z. Hu, F. Liu, D. Hong, L. Ma, H. Liu, X. Zhou, J. Chen, L. Pan, W. Chen, X. Li, H. Wang, Prevalence of chronic kidney disease in China:a cross-sectional survey, Lancet,379 (2012) 815-822.
[19]R. Agarwal, Epidemiology of chronic kidney disease among normotensives:but what is chronic kidney disease?, Hypertension,55 (2010) 1097-1099.
[20]L. Zhang, P. Zhang, F. Wang, L. Zuo, Y. Zhou, Y. Shi, G. Li, S. Jiao, Z. Liu, W. Liang, H. Wang, Prevalence and factors associated with CKD:a population study from Beijing, American journal of kidney diseases:the official journal of the National Kidney Foundation,51 (2008) 373-384.
[21]黄燕萍,上海城市社区成年人群慢性肾脏病流行病学研究,中华肾脏病杂志,24(2008)872-877.
[22]校彦勇,四川广汉市慢性肾脏病流行情况及其影响因素,中华肾脏病杂志,(2009)566-567.
[23]迪力木拉提,李增录,刘健等.新疆墨玉县农村维吾尔族成人慢性肾脏病流行 病学调查,中华肾脏病杂志,(2009)607-612.
[24]Y. Shan, Q. Zhang, Z. Liu, X. Hu, D. Liu, Prevalence and risk factors associated with chronic kidney disease in adults over 40 years:a population study from Central China, Nephrology (Carlton),15 (2010) 354-361.
[25]W. Chen, H. Wang, X. Dong, Q. Liu, H. Mao, J. Tan, J. Lin, F. Zhou, N. Luo, H. He, R.J. Johnson, S.F. Zhou, X. Yu, Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,24 (2009) 1205-1212.
[26]C.M. O'Seaghdha, V. Perkovic, T.H. Lam, S. McGinn, F. Barzi, D.F. Gu, A. Cass, I. Suh, P. Muntner, G.G. Giles, H. Ueshima, M. Woodward, R. Huxley, Blood pressure is a major risk factor for renal death:an analysis of 560 352 participants from the Asia-Pacific region, Hypertension,54 (2009) 509-515.
[27]D.C. Crews, L.C. Plantinga, E.R. Miller,3rd, R. Saran, E. Hedgeman, S.H. Saydah, D.E. Williams, N.R. Powe, Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States, Hypertension, 55(2010) 1102-1109.
[28]J.A. Staessen, L. Thijs, G. Mancia, G. Parati, E.T. O'Brien, Clinical trials with ambulatory blood pressure monitoring:fewer patients needed? Syst-Eur Investigators, Lancet,344 (1994) 1552-1556.
[29]N. Donner-Banzhoff, Y. Chan, J.P. Szalai, J. Hilditch,'Home hypertension': exploring the inverse white coat response, The British journal of general practice: the journal of the Royal College of General Practitioners,48 (1998) 1491-1495.
[30]T.G. Pickering, K. Davidson, W. Gerin, J.E. Schwartz, Masked hypertension, Hypertension,40 (2002) 795-796.
[31]Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004), Hypertension research:official journal of the Japanese Society of Hypertension,29 Suppl (2006) S1-105.
[32]T. Hedner, A. Himmelmann, S.E. Kjeldsen, Masked hypertension--a new entity and challenge for clinical hypertension research and management, Blood pressure,12 (2003) 261-263.
[33]D.W. McKay, M.G. Myers, P. Bolli, A. Chockalingam, Masked hypertension:a common but insidious presentation of hypertension, The Canadian journal of cardiology,22 (2006) 617-620.
[34]G. Bobrie, P. Clerson, J. Menard, N. Postel-Vinay, G. Chatellier, P.F. Plouin, Masked hypertension:a systematic review, Journal of hypertension,26 (2008) 1715-1725.
[35]谢晋湘,黄建凤,吴海英等,应用两种血压测量方法指导培哚普利抗高血压治疗的比较-中国APTH研究(中国动态血压监测与高血压治疗研究),高血压杂志,(2004)24-28.
[36]P. Verdecchia, G.P. Reboldi, F. Angeli, G Schillaci, J.E. Schwartz, T.G Pickering, Y. Imai, T. Ohkubo, K. Kario, Short-and long-term incidence of stroke in white-coat hypertension, Hypertension,45 (2005) 203-208.
[37]K.V. Towns, A. Kipioti, V. Long, M. McKibbin, C. Maubaret, V. Vaclavik, P. Ehsani, K. Springell, M. Kamal, R.S. Ramesar, D.A. Mackey, A.T. Moore, R. Mukhopadhyay, A.R. Webster, GC. Black, J. O'Sullivan, S.S. Bhattacharya, E.A. Pierce, J.D. Beggs, C.F. Inglehearn, Prognosis for splicing factor PRPF8 retinitis pigmentosa, novel mutations and correlation between human and yeast phenotypes, Hum Mutat,31 (2010) E1361-1376.
[38]E. Dolan, A. Stanton, L. Thijs, K. Hinedi, N. Atkins, S. McClory, E. Den Hond, P. McCormack, J.A. Staessen, E. O'Brien, Superiority of ambulatory over clinic blood pressure measurement in predicting mortality:the Dublin outcome study, Hypertension,46 (2005) 156-161.
[39]M.E. Ernst, B.L. Carter, C.J. Goerdt, J.J. Steffensmeier, B.B. Phillips, M.B. Zimmerman, GR. Bergus, Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure, Hypertension,47 (2006) 352-358.
[40]J.M. Mallion, P. Clerson, G. Bobrie, N. Genes, B. Vaisse, G Chatellier, Predictive factors for masked hypertension within a population of controlled hypertensives, Journal of hypertension,24 (2006) 2365-2370.
[41]R. Sega, G. Trocino, A. Lanzarotti, S. Carugo, G. Cesana, R. Schiavina, F. Valagussa, M. Bombelli, C. Giannattasio, A. Zanchetti, G Mancia, Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension:Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study), Circulation,104 (2001) 1385-1392.
[42]G Mancia, M. Bombelli, R. Facchetti, F. Madotto, F. Quarti-Trevano, G Grassi, R. Sega, Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension, Journal of hypertension,27 (2009) 1672-1678.
[43]J.E. Liu, M.J. Roman, R. Pini, J.E. Schwartz, T.G. Pickering, R.B. Devereux, Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure, Ann Intern Med,131 (1999) 564-572.
[44]T.W. Hansen, J. Jeppesen, S. Rasmussen, H. Ibsen, C. Torp-Pedersen, Ambulatory blood pressure and mortality:a population-based study, Hypertension,45 (2005) 499-504.
[45]T. Ohkubo, M. Kikuya, H. Metoki, K. Asayama, T. Obara, J. Hashimoto, K. Totsune, H. Hoshi, H. Satoh, Y. Imai, Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study, J Am Coll Cardiol,46 (2005)508-515.
[46]J.W. Sit, L. Sijian, E.M. Wong, Z. Yanling, W. Ziping, J. Jianqiang, C. Yanling, T.K. Wong, Prevalence and risk factors associated with prehypertension: identification of foci for primary prevention of hypertension, The Journal of cardiovascular nursing,25 (2010) 461-469.
[47]孔灵芝,中国慢性病防治规划解读,中国慢性病预防与控制,121(2012)502-503.
[48]F.M. Sacks, L.P. Svetkey, W.M. Vollmer, L.J. Appel, GA. Bray, D. Harsha, E. Obarzanek, P.R. Conlin, E.R. Miller,3rd, D.G. Simons-Morton, N. Karanja, P.H. Lin, Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group, The New England journal of medicine,344 (2001) 3-10.
[49]J.E. Neter, B.E. Stam, F.J. Kok, D.E. Grobbee, J.M. Geleijnse, Influence of weight reduction on blood pressure:a meta-analysis of randomized controlled trials, Hypertension,42 (2003) 878-884.
[50]J. He, D. Gu, X. Wu, J. Chen, X. Duan, P.K. Whelton, Effect of soybean protein on blood pressure:a randomized, controlled trial, Annals of internal medicine, 143 (2005) 1-9.
[51]孙香爱,陈雪萍,王花玲等.正常高值血压退休人群社区干预效果评价,中国公共卫生,27(2011)781-782.
[52]成丽娟,张述萍,刘芳等.不同干预措施预防正常高值血压人群发生高血压的效果,中华高血压杂志,(2011)652-657.
[53]常春,健康教育中的行为理论,中国健康教育,(2005)739-741.
[54]M. Monami, N. Marchionni, G. Masotti, E. Mannucci, IDF and ATP-Ⅲ definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients, Diabetes Obes Metab,9 (2007) 350-353.
[55]X.J. Meng, GH. Dong, D. Wang, M.M. Liu, Y.Q. Liu, Y. Zhao, W.W. Deng, S. Tian, X. Meng, H.Y. Zhang, Epidemiology of prehypertension and associated risk factors in urban adults from 33 communities in China--the CHPSNE study, Circulation journal:official journal of the Japanese Circulation Society,76 (2012) 900-906.
[56]李立明,中国居民2002年营养与健康状况调查,中华流行病学杂志,26(2005)56-62.
[57]G. Mancia, G De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S.D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J.L. Zamorano, S. Erdine, W. Kiowski, E. Agabiti-Rosei, E. Ambrosion, L.H. Lindholm, A. Manolis, P.M. Nilsson, J. Redon, M. Viigimaa, S. Adamopoulos, V. Bertomeu, D. Clement, C. Farsang, D. Gaita, G. Lip, J.M. Mallion, A.J. Manolis, E. O'Brien, P. Ponikowski, F. Ruschitzka, J. Tamargo, P. van Zwieten, B. Waeber, B. Williams, [ESH/ESC 2007 Guidelines for the management of arterial hypertension], Revista espanola de cardiologia,60 (2007) 968 e961-994.
[58]G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Boudier, A. Zanchetti,2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension:ESH-ESC Task Force on the Management of Arterial Hypertension, Journal of hypertension, 25 (2007) 1751-1762.
[59]L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lindgren, Q. Qiao, S.G. Priori, J.J. Blanc, A. Budaj, J. Camm, V. Dean, J. Deckers, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J. Tamargo, J.L. Zamorano, J.W. Deckers, M. Bertrand, B. Charbonnel, E. Erdmann, E. Ferrannini, A. Flyvbjerg, H. Gohlke, J.R. Juanatey, I. Graham, P.F. Monteiro, K. Parhofer, K. Pyorala, I. Raz, G. Schernthaner, M. Volpe, D. Wood, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J,28 (2007) 88-136.
[60]N. Chapman, R. Huxley, C. Anderson, M.G Bousser, J. Chalmers, S. Colman, S. Davis, G. Donnan, S. MacMahon, B. Neal, C. Warlow, M. Woodward, Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history:the PROGRESS Trial, Stroke,35(2004)116-121.
[61]L.J. Appel, The verdict from ALLHAT--thiazide diuretics are the preferred initial therapy for hypertension, JAMA,288 (2002) 3039-3042.
[62]S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial, Lancet, 363(2004)2022-2031.
[63]M.J. O'Donnell, D. Xavier, L. Liu, H. Zhang, S.L. Chin, P. Rao-Melacini, S. Rangarajan, S. Islam, P. Pais, M.J. McQueen, C. Mondo, A. Damasceno, P. Lopez-Jaramillo, G.J. Hankey, A.L. Dans, K. Yusoff, T. Truelsen, H.C. Diener, R.L. Sacco, D. Ryglewicz, A. Czlonkowska, C. Weimar, X. Wang, S. Yusuf, Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study):a case-control study, Lancet,376 (2010) 112-123.
[64]P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial, Lancet,361 (2003) 1149-1158.
[65]L.B. Goldstein, R. Adams, M.J. Alberts, L.J. Appel, L.M. Brass, C.D. Bushnell, A. Culebras, T.J. Degraba, P.B. Gorelick, J.R. Guyton, R.G. Hart, G. Howard, M. Kelly-Hayes, J.V. Nixon, R.L. Sacco, Primary prevention of ischemic stroke:a guideline from the American Heart Association/American Stroke Association Stroke Council:cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline, Stroke, 37(2006)1583-1633.
[66]N.M. Kaplan, Trial of Preventing Hypertension (TROPHY):design and 2-year progress report, Hypertension,44 (2004) 125-126.
[67]X. Peng, Y. Li, J. Li, F.Y. Liu, Y.M. Peng, L. Sun, L.T. Zhou, W.B. Tang, Y.Y. He, X. Chen, L.J. Yang, J. Chen, J.W. Wu, J.D. Peng, D.J. Wang, R.H. Yu, [Metabolic syndrome and chronic kidney disease in a rural adult population of Hunan province, China], Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi,30 (2009) 1221-1225.
[68]李瑛,湖南省长沙县慢性肾脏病的流行病学研究,中华肾脏病杂志,(2010)123-127.
[69]K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification, American journal of kidney diseases:the official journal of the National Kidney Foundation,39 (2002) S1-266.
[70]Y.C. Ma, L. Zuo, J.H. Chen, Q. Luo, X.Q. Yu, Y. Li, J.S. Xu, S.M. Huang, L.N. Wang, W. Huang, M. Wang, GB. Xu, H.Y. Wang, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease, Journal of the American Society of Nephrology:JASN,17 (2006) 2937-2944.
[71]J. Coresh, E. Selvin, L.A. Stevens, J. Manzi, J.W. Kusek, P. Eggers, F. Van Lente, A.S. Levey, Prevalence of chronic kidney disease in the United States, JAMA: the journal of the American Medical Association,298 (2007) 2038-2047.
[72]S.J. Chadban, E.M. Briganti, P.G Kerr, D.W. Dunstan, T.A. Welborn, P.Z. Zimmet, R.C. Atkins, Prevalence of kidney damage in Australian adults:The AusDiab kidney study, Journal of the American Society of Nephrology:JASN, 14(2003)S131-138.
[73]D. Reyes, S.Q. Lew, P.L. Kimmel, Gender differences in hypertension and kidney disease, The Medical clinics of North America,89 (2005) 613-630.
[74]范文娟,新疆地区成年体检人群中慢性肾脏病患病率及相关危险因素调查,中华肾脏病杂志,27(2011)345-348.
[75]T.V. Perneger, F.J. Nieto, P.K. Whelton, M.J. Klag, G.W. Comstock, M. Szklo, A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study, JAMA:the journal of the American Medical Association,269 (1993) 488-493.
[76]M.V. Rao, Y. Qiu, C. Wang, G. Bakris, Hypertension and CKD:Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES),1999-2004, American journal of kidney diseases:the official journal of the National Kidney Foundation,51 (2008) S30-37.
[77]E. Pimenta, S. Oparil, Prehypertension:epidemiology, consequences and treatment, Nature reviews. Nephrology,6 (2010) 21-30.
[78]Y. Ishikawa, J. Ishikawa, S. Ishikawa, E. Kajii, J.E. Schwartz, T.G. Pickering, K. Kario, Prehypertension and the risk for cardiovascular disease in the Japanese general population:the Jichi Medical School Cohort Study, Journal of hypertension,28 (2010) 1630-1637.
[79]G Chen, X. Lai, Q. Jiang, F. Chen, N. Chen, H. Huang, J. Liang, L. Li, J. Wen, L. Lin, J. Yao, Cardiovascular disease (CVD) risk, insulin resistance and beta-cell function in prehypertension population of China, Atherosclerosis,217 (2011) 279-285.
[80]M.J. Kim, N.K. Lim, H.Y. Park, Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea:the Korean genome and epidemiology study, BMC public health,12 (2012) 960.
[81]Y. Yano, S. Fujimoto, Y. Sato, T. Konta, K. Iseki, T. Moriyama, K. Yamagata, K. Tsuruya, H. Yoshida, K. Asahi, I. Kurahashi, Y. Ohashi, T. Watanabe, Association between prehypertension and chronic kidney disease in the Japanese general population, Kidney international,81 (2012) 293-299.
[82]D.D. Maki, J.Z. Ma, T.A. Louis, B.L. Kasiske, Long-term effects of antihypertensive agents on proteinuria and renal function, Archives of internal medicine,155 (1995) 1073-1080.
[83]J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, A.S. Levey, Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey, American journal of kidney diseases:the official journal of the National Kidney Foundation,41 (2003) 1-12.
[84]C.M. Clase, A.X. Garg, B.A. Kiberd, Prevalence of low glomerular filtration rate in nondiabetic Americans:Third National Health and Nutrition Examination Survey (NHANES Ⅲ), Journal of the American Society of Nephrology:JASN, 13 (2002) 1338-1349.
[85]M. Kurella, J.C. Lo, GM. Chertow, Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults, Journal of the American Society of Nephrology:JASN,16 (2005) 2134-2140.
[86]N.L. Edwards, The role of hyperuricemia and gout in kidney and cardiovascular disease, Cleveland Clinic journal of medicine,75 Suppl 5 (2008) S13-16.
[87]R.S. Vasan, A. Beiser, S. Seshadri, M.G. Larson, W.B. Kannel, R.B. D'Agostino, D. Levy, Residual lifetime risk for developing hypertension in middle-aged women and men:The Framingham Heart Study, JAMA,287 (2002) 1003-1010.
[88]H. Tomiyama, C. Matsumoto, J. Yamada, M. Yoshida, M. Odaira, K. Shiina, M. Nagata, A. Yamashina, Predictors of progression from prehypertension to hypertension in Japanese men, Am J Hypertens,22 (2009) 630-636.
[89]S.A. Williams, E.L. Michelson, V.A. Cain, M. Yang, S.D. Nesbitt, B.M. Egan, S. Julius, An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY), J Clin Hypertens (Greenwich),10 (2008) 436-442.
[90]P.K. Li, B.C. Kwan, C.B. Leung, T.H. Kwan, K.M. Wong, S.L. Lui, W.K. Tsang, C.C. Mak, S.K. Mak, A.W. Yu, S. Tang, Prevalence of silent kidney disease in Hong Kong:the screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program, Kidney Int Suppl, (2005) S36-40.
[91]陈.王.董.何.刘.骆.谭.林.聂.毛.陈.余学清,广州市城区普通人群中慢性肾脏病的流行病学研究,中华肾脏病杂志,(2007)68-74.
[92]刘.刘.胡.邢.施学忠,郑州市城区成年人慢性肾脏病流行病学调查,中华肾脏病杂志,(2008)355-359.
[93]N. Chen, W. Wang, Y. Huang, P. Shen, D. Pei, H. Yu, H. Shi, Q. Zhang, J. Xu, Y. Lv, Q. Fan, Community-based study on CKD subjects and the associated risk factors, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,24 (2009)2117-2123.
[94]K. Kario, J. Ishikawa, T.G Pickering, S. Hoshide, K. Eguchi, M. Morinari, Y. Hoshide, T. Kuroda, K. Shimada, Morning hypertension:the strongest independent risk factor for stroke in elderly hypertensive patients, Hypertension research:official journal of the Japanese Society of Hypertension,29 (2006) 581-587.
[95]R. Karasek, Job strain and the prevalence and outcome of coronary artery disease, Circulation,94 (1996) 1140-1141.
[96]S.D. Pierdomenico, D. Lapenna, A. Bucci, R. Di Tommaso, R. Di Mascio, B.M. Manente, M.P. Caldarella, M. Neri, F. Cuccurullo, A. Mezzetti, Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension, Am J Hypertens,18 (2005) 1422-1428.
[98 K. Bjorklund, L. Lind, B. Zethelius, B. Andren, H. Lithell, Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men, Circulation,107 (2003) 1297-1302.
[98]C. Selenta, B.E. Hogan, W. Linden, How often do office blood pressure measurements fail to identify true hypertension? An exploration of white-coat normotension, Archives of family medicine,9 (2000) 533-540.
[99]S.D. Pierdomenico, G. Pannarale, F. Rabbia, D. Lapenna, R. Licitra, M. Zito, M. Campanella, C. Gaudio, F. Veglio, F. Cuccurullo, Prognostic relevance of masked hypertension in subjects with prehypertension, Am J Hypertens,21 (2008) 879-883.
[100]R.H. Fagard, C. Van Den Broeke, P. De Cort, Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice, Journal of human hypertension,19 (2005) 801-807.
[101]T. Theorell, R.A. Karasek, Current issues relating to psychosocial job strain and cardiovascular disease research, J Occup Health Psychol,1 (1996) 9-26.
[102]G. Cesana, R. Sega, M. Ferrario, P. Chiodini, G Corrao, G. Mancia, Job strain and blood pressure in employed men and women:a pooled analysis of four northern italian population samples, Psychosom Med,65 (2003) 558-563.
[103]S. Uchiyama, T. Kurasawa, T. Sekizawa, H. Nakatsuka, Job strain and risk of cardiovascular events in treated hypertensive Japanese workers:hypertension follow-up group study, J Occup Health,47 (2005) 102-111.
[104]G. Cesana, M. Ferrario, R. Sega, C. Milesi, G. De Vito, G. Mancia, A. Zanchetti, Job strain and ambulatory blood pressure levels in a population-based employed sample of men from northern Italy, Scand J Work Environ Health,22 (1996) 294-305.
[105]S.W. Tobe, A. Kiss, S. Sainsbury, M. Jesin, R. Geerts, B. Baker, The impact of job strain and marital cohesion on ambulatory blood pressure during 1 year:the double exposure study, American journal of hypertension,20 (2007) 148-153.
[106]C. Brisson, N. Laflamme, J. Moisan, A. Milot, B. Masse, M. Vezina, Effect of family responsibilities and job strain on ambulatory blood pressure among white-collar women, Psychosom Med,61 (1999) 205-213.
[107]吴寿岭,张子强,宋胜斌,么太成,李云,王剑利,王娜,金成,李金锋,高血压前期人群血压转归及其影响因素,中华心血管病杂志,38(2010)145-152.
[108]E.R. Miller,3rd, T.P. Erlinger, D.R. Young, M. Jehn, J. Charleston, D. Rhodes, S.K. Wasan, L.J. Appel, Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT), Hypertension,40 (2002) 612-618.
[109]V.J. Stevens, E. Obarzanek, N.R. Cook, I.M. Lee, L.J. Appel, D. Smith West, N.C. Milas, M. Mattfeldt-Beman, L. Belden, C. Bragg, M. Millstone, J. Raczynski, A. Brewer, B. Singh, J. Cohen, Long-term weight loss and changes in blood pressure:results of the Trials of Hypertension Prevention, phase Ⅱ, Annals of internal medicine,134 (2001) 1-11.
[110]K.G. Alberti, P. Zimmet, J. Shaw, The metabolic syndrome--a new worldwide definition, Lancet,366 (2005) 1059-1062.
[111]P.J. Elmer, E. Obarzanek, W.M. Vollmer, D. Simons-Morton, V.J. Stevens, D.R. Young, P.H. Lin, C. Champagne, D.W. Harsha, L.P. Svetkey, J. Ard, P.J. Brantley, M.A. Proschan, T.P. Erlinger, L.J. Appel, Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial, Annals of internal medicine,144 (2006) 485-495.
[112]L.P. Svetkey, Management of prehypertension, Hypertension,45 (2005) 1056-1061.
[113]P. Varkey, A. Sathananthan, A. Scheifer, S. Bhagra, A. Fujiyoshi, A. Tom, M.H. Murad, Using quality-improvement techniques to enhance patient education and counselling of diagnosis and management, Quality in primary care,17 (2009) 205-213.
1 Pickering TG, Davidson K, Gerin W, et al. Masked hypertension[J]. Hypertension, 2002,40(6):795-796.
2. Pickering T. White coat hypertension'--should it be treated or not[J]? Cleveland Clinic journal of medicine.2002;69(8):584-585.
3. Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Journal of hypertension,2007, 25(6):1105-1187.
4. Cacciolati C, Hanon O, Alperovitch A, et al. Masked hypertension in the elderly: cross-sectional analysis of a population-based sample [J]. Am J Hypertens,2011, 24(6):674-680.
5. Hanninen MR, Niiranen TJ, Puukka PJ, et al. Determinants of masked hypertension in the general population:the Finn-Home study [J]. Journal of hypertension,2011,29(10):1880-1888.
6. Zhou J, Liu C, Shan P, et al. Prevalence and distinguishing features of masked hypertension in type 2 diabetic patients [J]. Journal of diabetes and its complications, 2013,27(1):82-86.
7. Baguet JP, Levy P, Barone-Rochette G, et al. Masked hypertension in obstructive sleep apnea syndrome [J]. Journal of hypertension,2008,26(5):885-892.
8. Sobrino J, Domenech M, Camafort M, et al. Prevalence of masked hypertension in a cohort of controlled hypertensive patients in Spain[J]. Med Clin, 2011,136(14):607-612.
9. Andrikou I, Tsioufis C, Dimitriadis K, et al. Similar levels of low-grade inflammation and arterial stiffness in masked and white-coat hypertension: comparisons with sustained hypertension and normotension[J]. Blood pressure monitoring,2011,16(5):218-223.
10. Andalib A, Akhtari S, Rigal R, et al. Determinants of masked hypertension in hypertensive patients treated in a primary care setting[J]. Internal medicine journal,2012,42(3):260-266.
11. Verberk WJ, Kessels AG, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension:a meta-analysis[J]. American journal of hypertension,2008,21 (9):969-975.
12. Schultz MG, Hare JL, Marwick TH, et al. Masked hypertension is "unmasked" by low-intensity exercise blood pressure[J]. Blood pressure,2011,20(5):284-289.
13. Ostrow V, Wu S, Aguilar A, et al. Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents[J]. The Journal of pediatrics,2011,158(4):628-633.
14. Asayama K, Sato A, Ohkubo T, et al. The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome:the Ohasama study[J]. Hypertens Res,2009,32(6),438-443.
15. Kim SK, Bae JH, Nah DY, et al. Frequency and related factors of masked hypertension at a worksite in Korea[J]. Journal of preventive medicine and public health,2011,44(3):131-139.
16. Ogedegbe G, Pickering TG, Clemow L, et al. The misdiagnosis of hypertension: the role of patient anxiety[J]. Archives of internal medicine,2008,168(22): 2459-2465.
17. Uzu T, Nakao K, Kume S, et al. High sodium intake is associated with masked hypertension in Japanese patients with type 2 diabetes and treated hypertension[J]. American journal of hypertension,2012,25(11):1170-1174.
18. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring:executive summary:a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association[J]. Hypertension, 2008,52(1):1-9.
19. Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension[J]. Hypertension research,2012,35(7):750-755.
20. Kawano Y, Horio T, Matayoshi T, et al. Masked hypertension:subtypes and target organ damage[J]. Clin Exp Hypertens,2008,30(3):289-296.
21. Cuspidi C, Negri F, Sala C, et al. Masked hypertension and echocardiographic left ventricular hypertrophy:an updated overview[J]. Blood pressure monitoring, 2012,17(1):8-13.
22. Takeno K, Mita T, Nakayama S, et al. Masked hypertension, endothelial dysfunction, and arterial stiffness in type 2 diabetes mellitus:a pilot study[J]. Am J Hypertens,2012,25(2):165-170.
23.傅坤发,胡建,何畏,等.隐性高血压患者内皮依赖性血管舒张功能的变化[J].中华高血压杂志,2010,18(03)：259-262.
24. Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Endothelial-dependent flow-mediated dilation in African Americans with masked-hypertension[J]. American journal of hypertension,2011,24(10):1102-1107.
25. Hara A, Ohkubo T, Kondo T, et al. Detection of silent cerebrovascular lesions in individuals with 'masked' and 'white-coat' hypertension by home blood pressure measurement:the Ohasama study[J]. Journal of hypertension,2009,27(5):1049-1055.
26. Ishikawa J, Hoshide S, Eguchi K, et al. Masked hypertension defined by ambulatory blood pressure monitoring is associated with an increased serum glucose level and urinary albumin-creatinine ratio[J]. J Clin Hypertens,2010,12(8):578-587.
27. Bombelli M, Sega R, Facchetti R, et al. Prevalence and clinical significance of a greater ambulatory versus office blood pressure ('reversed white coat' condition) in a general population[J]. Journal of hypertension,2005,23(3):513-520.
28. Ormezzano O, Baguet JP, Francois P, et al. Is there any real target organ damage associated with white-coat normotension[J]? Clinical autonomic research,2004,14(3):160-166.
29. Yoon HJ, Ahn Y, Park JB, et al. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension [J]? Clin Exp Hypertens,2010,32(7):480-485.
30. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease[J]. Hypertension,2009,53(1):20-27.
31. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients[J]. JAMA,2004,291(11):1342-1349.
32. Pickering TG, White WB, Giles TD, et al. When and how to use self (home) and ambulatory blood pressure monitoring[J]. Journal of the American Society of Hypertension,2010,4(2):56-61.
33. Pickering TG Should doctors still measure blood pressure[J]? J Clin Hypertens, 2006,8(6):394-396.
34. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects:an updated meta analysis[J]. American journal of hypertension,2011,24(1):52-58.
35. Hanninen MR, Niiranen TJ, Puukka PJ, et al. Prognostic significance of masked and white-coat hypertension in the general population:the Finn-Home Study [J]. Journal of hypertension,2012,30(4):705-712.
36. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med,2008,358(18):1887-1898.
37. Cushman WC, Davis BR, Pressel SL, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial[J]. J Clin Hypertens,2012,14(1):20-31.
38. Phillips RA. Controversies in blood pressure goal guidelines and masked hypertension[J]. Ann N Y Acad Sci,2012,1254(4):115-122.
39. Ohta Y, Tsuchihashi T, Kiyohara K. Consequence of masked hypertension in treated hypertensive outpatients:1-year follow-up study [J]. Clin Exp Hypertens,2011,33(4):270-274.
40. Drager LF, Pedrosa RP, Diniz PM, et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea[J]. Hypertension,2011,57(3):549-555.
41. Gu Q, Burt VL, Paulose-Ram R, et al. High blood pressure and cardiovascular disease mortality risk among U.S. adults:the third National Health and Nutrition Examination Survey mortality follow-up study [J]. Annals of epidemiology, 2008,18(4):302-309.
42. Furusawa EA, Filho UD, Junior DM, et al. Home and ambulatory blood pressure to identify white coat and masked hypertension in the pediatric patient[J]. Am J Hypertens,2011,24(8):893-897.
43. van der Wel MC, Buunk IE, van Weel C, et al. A novel approach to office blood pressure measurement:30-minute office blood pressure vs daytime ambulatory blood pressure[J]. Ann Fam Med,2011,9(2):128-135.
44. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass:the Masked Hypertension Study[J]. Am J Hypertens,2012,25(6):664-671.
45. Pickering TG. The natural history of hypertension:prehypertension or masked hypertension[J]? J Clin Hypertens,2007,9(10):807-810.
46. Enstrom IE, Pennert KM. Masked hypertension in untreated normotensives: difference between a work day and a leisure day[J]? Blood Press Monit,2011,16(1):7-10.
[2]A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo, Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, Jr., E.J. Roccella, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:the JNC 7 report, JAMA:the journal of the American Medical Association,289 (2003) 2560-2572.
[3]刘力生.2004年中国高血压防治指南(实用本),中华心血管病杂志,(2004)9-13.
[4]刘力生.中国高血压防治指南2010,中华高血压杂志,19(2011)701-743.
[5]A.I. Qureshi, M.F. Suri, J.F. Kirmani, A.A. Divani, Prevalence and trends of prehypertension and hypertension in United States:National Health and Nutrition Examination Surveys 1976 to 2000, Medical science monitor international medical journal of experimental and clinical research,11 (2005) CR403-409.
[6]李立明,饶克勤,孔灵芝等.中国居民营养与健康状况调查技术执行组,中国居民2002年营养与健康状况调查,中华流行病学杂志,(2005)478-484.
[7]胡世莲,吴蕾,方向等.安徽省中部地区职业人群正常高值血压状况及危险因素分析,中国慢性病预防与控制,107(2010)223-225.
[8]王薇,赵冬,孙佳艺等.中国正常高值血压人群的心血管病发病危险,中华高血压杂志,96(2007)984-987.
[9]李巧先,张春梅.包头钢铁公司职工高血压患病及血压分布现状,中国慢性病预防与控制,93(2008)87-88.
[10]唐晓鸿,袁洪,曾丽雄等.长沙地区公务员正常高值血压、高血压流行现状及危险因素分析,中国动脉硬化杂志,102(2009)409-413.
[11]E. Manios, G. Tsivgoulis, E. Koroboki, K. Stamatelopoulos, C. Papamichael, S. Toumanidis, E. Stamboulis, K. Vemmos, N. Zakopoulos, Impact of prehypertension on common carotid artery intima-media thickness and left ventricular mass, Stroke,40 (2009) 1515-1518.
[12]M.J. Pletcher, K. Bibbins-Domingo, C.E. Lewis, G.S. Wei, S. Sidney, J.J. Carr, E. Vittinghoff, C.E. McCulloch, S.B. Hulley, Prehypertension during young adulthood and coronary calcium later in life, Ann Intern Med,149 (2008) 91-99.
[13]B.R. Weil, B.L. Stauffer, J.J. Greiner, C.A. DeSouza, Prehypertension is associated with impaired nitric oxide-mediated endothelium-dependent vasodilation in sedentary adults, Am J Hypertens,24 (2011) 976-981.
[14]M.R. Markus, J. Stritzke, W. Lieb, B. Mayer, A. Luchner, A. Doring, U. Keil, H.W. Hense, H. Schunkert, Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function:the MONICA/KORA Augsburg study, J Hypertens,26 (2008) 2040-2049.
[15]N.M. Shara, H.E. Resnick, L. Lu, J. Xu, S. Vupputuri, B.V. Howard, J.G Umans, Decreased GFR estimated by MDRD or Cockcroft-Gault equation predicts incident CVD:the strong heart study, Journal of nephrology,22 (2009) 373-380.
[16]A. Kiyosue, Y. Hirata, J. Ando, H. Fujita, T. Morita, M. Takahashi, D. Nagata, T. Kohro, Y. Imai, R. Nagai, Relationship between renal dysfunction and severity of coronary artery disease in Japanese patients, Circulation journal:official journal of the Japanese Circulation Society,74 (2010) 786-791.
[17]F. Wang, P. Ye, L. Luo, W. Xiao, H. Wu, Association of risk factors for cardiovascular disease and glomerular filtration rate:a community-based study of 4,925 adults in Beijing, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,25 (2010) 3924-3931.
[18]L. Zhang, F. Wang, L. Wang, W. Wang, B. Liu, J. Liu, M. Chen, Q. He, Y. Liao, X. Yu, N. Chen, J.E. Zhang, Z. Hu, F. Liu, D. Hong, L. Ma, H. Liu, X. Zhou, J. Chen, L. Pan, W. Chen, X. Li, H. Wang, Prevalence of chronic kidney disease in China:a cross-sectional survey, Lancet,379 (2012) 815-822.
[19]R. Agarwal, Epidemiology of chronic kidney disease among normotensives:but what is chronic kidney disease?, Hypertension,55 (2010) 1097-1099.
[20]L. Zhang, P. Zhang, F. Wang, L. Zuo, Y. Zhou, Y. Shi, G. Li, S. Jiao, Z. Liu, W. Liang, H. Wang, Prevalence and factors associated with CKD:a population study from Beijing, American journal of kidney diseases:the official journal of the National Kidney Foundation,51 (2008) 373-384.
[21]黄燕萍,上海城市社区成年人群慢性肾脏病流行病学研究,中华肾脏病杂志,24(2008)872-877.
[22]校彦勇,四川广汉市慢性肾脏病流行情况及其影响因素,中华肾脏病杂志,(2009)566-567.
[23]迪力木拉提,李增录,刘健等.新疆墨玉县农村维吾尔族成人慢性肾脏病流行 病学调查,中华肾脏病杂志,(2009)607-612.
[24]Y. Shan, Q. Zhang, Z. Liu, X. Hu, D. Liu, Prevalence and risk factors associated with chronic kidney disease in adults over 40 years:a population study from Central China, Nephrology (Carlton),15 (2010) 354-361.
[25]W. Chen, H. Wang, X. Dong, Q. Liu, H. Mao, J. Tan, J. Lin, F. Zhou, N. Luo, H. He, R.J. Johnson, S.F. Zhou, X. Yu, Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,24 (2009) 1205-1212.
[26]C.M. O'Seaghdha, V. Perkovic, T.H. Lam, S. McGinn, F. Barzi, D.F. Gu, A. Cass, I. Suh, P. Muntner, G.G. Giles, H. Ueshima, M. Woodward, R. Huxley, Blood pressure is a major risk factor for renal death:an analysis of 560 352 participants from the Asia-Pacific region, Hypertension,54 (2009) 509-515.
[27]D.C. Crews, L.C. Plantinga, E.R. Miller,3rd, R. Saran, E. Hedgeman, S.H. Saydah, D.E. Williams, N.R. Powe, Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States, Hypertension, 55(2010) 1102-1109.
[28]J.A. Staessen, L. Thijs, G. Mancia, G. Parati, E.T. O'Brien, Clinical trials with ambulatory blood pressure monitoring:fewer patients needed? Syst-Eur Investigators, Lancet,344 (1994) 1552-1556.
[29]N. Donner-Banzhoff, Y. Chan, J.P. Szalai, J. Hilditch,'Home hypertension': exploring the inverse white coat response, The British journal of general practice: the journal of the Royal College of General Practitioners,48 (1998) 1491-1495.
[30]T.G. Pickering, K. Davidson, W. Gerin, J.E. Schwartz, Masked hypertension, Hypertension,40 (2002) 795-796.
[31]Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004), Hypertension research:official journal of the Japanese Society of Hypertension,29 Suppl (2006) S1-105.
[32]T. Hedner, A. Himmelmann, S.E. Kjeldsen, Masked hypertension--a new entity and challenge for clinical hypertension research and management, Blood pressure,12 (2003) 261-263.
[33]D.W. McKay, M.G. Myers, P. Bolli, A. Chockalingam, Masked hypertension:a common but insidious presentation of hypertension, The Canadian journal of cardiology,22 (2006) 617-620.
[34]G. Bobrie, P. Clerson, J. Menard, N. Postel-Vinay, G. Chatellier, P.F. Plouin, Masked hypertension:a systematic review, Journal of hypertension,26 (2008) 1715-1725.
[35]谢晋湘,黄建凤,吴海英等,应用两种血压测量方法指导培哚普利抗高血压治疗的比较-中国APTH研究(中国动态血压监测与高血压治疗研究),高血压杂志,(2004)24-28.
[36]P. Verdecchia, G.P. Reboldi, F. Angeli, G Schillaci, J.E. Schwartz, T.G Pickering, Y. Imai, T. Ohkubo, K. Kario, Short-and long-term incidence of stroke in white-coat hypertension, Hypertension,45 (2005) 203-208.
[37]K.V. Towns, A. Kipioti, V. Long, M. McKibbin, C. Maubaret, V. Vaclavik, P. Ehsani, K. Springell, M. Kamal, R.S. Ramesar, D.A. Mackey, A.T. Moore, R. Mukhopadhyay, A.R. Webster, GC. Black, J. O'Sullivan, S.S. Bhattacharya, E.A. Pierce, J.D. Beggs, C.F. Inglehearn, Prognosis for splicing factor PRPF8 retinitis pigmentosa, novel mutations and correlation between human and yeast phenotypes, Hum Mutat,31 (2010) E1361-1376.
[38]E. Dolan, A. Stanton, L. Thijs, K. Hinedi, N. Atkins, S. McClory, E. Den Hond, P. McCormack, J.A. Staessen, E. O'Brien, Superiority of ambulatory over clinic blood pressure measurement in predicting mortality:the Dublin outcome study, Hypertension,46 (2005) 156-161.
[39]M.E. Ernst, B.L. Carter, C.J. Goerdt, J.J. Steffensmeier, B.B. Phillips, M.B. Zimmerman, GR. Bergus, Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure, Hypertension,47 (2006) 352-358.
[40]J.M. Mallion, P. Clerson, G. Bobrie, N. Genes, B. Vaisse, G Chatellier, Predictive factors for masked hypertension within a population of controlled hypertensives, Journal of hypertension,24 (2006) 2365-2370.
[41]R. Sega, G. Trocino, A. Lanzarotti, S. Carugo, G. Cesana, R. Schiavina, F. Valagussa, M. Bombelli, C. Giannattasio, A. Zanchetti, G Mancia, Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension:Data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study), Circulation,104 (2001) 1385-1392.
[42]G Mancia, M. Bombelli, R. Facchetti, F. Madotto, F. Quarti-Trevano, G Grassi, R. Sega, Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension, Journal of hypertension,27 (2009) 1672-1678.
[43]J.E. Liu, M.J. Roman, R. Pini, J.E. Schwartz, T.G. Pickering, R.B. Devereux, Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure, Ann Intern Med,131 (1999) 564-572.
[44]T.W. Hansen, J. Jeppesen, S. Rasmussen, H. Ibsen, C. Torp-Pedersen, Ambulatory blood pressure and mortality:a population-based study, Hypertension,45 (2005) 499-504.
[45]T. Ohkubo, M. Kikuya, H. Metoki, K. Asayama, T. Obara, J. Hashimoto, K. Totsune, H. Hoshi, H. Satoh, Y. Imai, Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study, J Am Coll Cardiol,46 (2005)508-515.
[46]J.W. Sit, L. Sijian, E.M. Wong, Z. Yanling, W. Ziping, J. Jianqiang, C. Yanling, T.K. Wong, Prevalence and risk factors associated with prehypertension: identification of foci for primary prevention of hypertension, The Journal of cardiovascular nursing,25 (2010) 461-469.
[47]孔灵芝,中国慢性病防治规划解读,中国慢性病预防与控制,121(2012)502-503.
[48]F.M. Sacks, L.P. Svetkey, W.M. Vollmer, L.J. Appel, GA. Bray, D. Harsha, E. Obarzanek, P.R. Conlin, E.R. Miller,3rd, D.G. Simons-Morton, N. Karanja, P.H. Lin, Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group, The New England journal of medicine,344 (2001) 3-10.
[49]J.E. Neter, B.E. Stam, F.J. Kok, D.E. Grobbee, J.M. Geleijnse, Influence of weight reduction on blood pressure:a meta-analysis of randomized controlled trials, Hypertension,42 (2003) 878-884.
[50]J. He, D. Gu, X. Wu, J. Chen, X. Duan, P.K. Whelton, Effect of soybean protein on blood pressure:a randomized, controlled trial, Annals of internal medicine, 143 (2005) 1-9.
[51]孙香爱,陈雪萍,王花玲等.正常高值血压退休人群社区干预效果评价,中国公共卫生,27(2011)781-782.
[52]成丽娟,张述萍,刘芳等.不同干预措施预防正常高值血压人群发生高血压的效果,中华高血压杂志,(2011)652-657.
[53]常春,健康教育中的行为理论,中国健康教育,(2005)739-741.
[54]M. Monami, N. Marchionni, G. Masotti, E. Mannucci, IDF and ATP-Ⅲ definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients, Diabetes Obes Metab,9 (2007) 350-353.
[55]X.J. Meng, GH. Dong, D. Wang, M.M. Liu, Y.Q. Liu, Y. Zhao, W.W. Deng, S. Tian, X. Meng, H.Y. Zhang, Epidemiology of prehypertension and associated risk factors in urban adults from 33 communities in China--the CHPSNE study, Circulation journal:official journal of the Japanese Circulation Society,76 (2012) 900-906.
[56]李立明,中国居民2002年营养与健康状况调查,中华流行病学杂志,26(2005)56-62.
[57]G. Mancia, G De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S.D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J.L. Zamorano, S. Erdine, W. Kiowski, E. Agabiti-Rosei, E. Ambrosion, L.H. Lindholm, A. Manolis, P.M. Nilsson, J. Redon, M. Viigimaa, S. Adamopoulos, V. Bertomeu, D. Clement, C. Farsang, D. Gaita, G. Lip, J.M. Mallion, A.J. Manolis, E. O'Brien, P. Ponikowski, F. Ruschitzka, J. Tamargo, P. van Zwieten, B. Waeber, B. Williams, [ESH/ESC 2007 Guidelines for the management of arterial hypertension], Revista espanola de cardiologia,60 (2007) 968 e961-994.
[58]G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Boudier, A. Zanchetti,2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension:ESH-ESC Task Force on the Management of Arterial Hypertension, Journal of hypertension, 25 (2007) 1751-1762.
[59]L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, K. Malmberg, S. Priori, J. Ostergren, J. Tuomilehto, I. Thrainsdottir, I. Vanhorebeek, M. Stramba-Badiale, P. Lindgren, Q. Qiao, S.G. Priori, J.J. Blanc, A. Budaj, J. Camm, V. Dean, J. Deckers, K. Dickstein, J. Lekakis, K. McGregor, M. Metra, J. Morais, A. Osterspey, J. Tamargo, J.L. Zamorano, J.W. Deckers, M. Bertrand, B. Charbonnel, E. Erdmann, E. Ferrannini, A. Flyvbjerg, H. Gohlke, J.R. Juanatey, I. Graham, P.F. Monteiro, K. Parhofer, K. Pyorala, I. Raz, G. Schernthaner, M. Volpe, D. Wood, Guidelines on diabetes, pre-diabetes, and cardiovascular diseases:executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD), Eur Heart J,28 (2007) 88-136.
[60]N. Chapman, R. Huxley, C. Anderson, M.G Bousser, J. Chalmers, S. Colman, S. Davis, G. Donnan, S. MacMahon, B. Neal, C. Warlow, M. Woodward, Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history:the PROGRESS Trial, Stroke,35(2004)116-121.
[61]L.J. Appel, The verdict from ALLHAT--thiazide diuretics are the preferred initial therapy for hypertension, JAMA,288 (2002) 3039-3042.
[62]S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial, Lancet, 363(2004)2022-2031.
[63]M.J. O'Donnell, D. Xavier, L. Liu, H. Zhang, S.L. Chin, P. Rao-Melacini, S. Rangarajan, S. Islam, P. Pais, M.J. McQueen, C. Mondo, A. Damasceno, P. Lopez-Jaramillo, G.J. Hankey, A.L. Dans, K. Yusoff, T. Truelsen, H.C. Diener, R.L. Sacco, D. Ryglewicz, A. Czlonkowska, C. Weimar, X. Wang, S. Yusuf, Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study):a case-control study, Lancet,376 (2010) 112-123.
[64]P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, J. Ostergren, Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial, Lancet,361 (2003) 1149-1158.
[65]L.B. Goldstein, R. Adams, M.J. Alberts, L.J. Appel, L.M. Brass, C.D. Bushnell, A. Culebras, T.J. Degraba, P.B. Gorelick, J.R. Guyton, R.G. Hart, G. Howard, M. Kelly-Hayes, J.V. Nixon, R.L. Sacco, Primary prevention of ischemic stroke:a guideline from the American Heart Association/American Stroke Association Stroke Council:cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline, Stroke, 37(2006)1583-1633.
[66]N.M. Kaplan, Trial of Preventing Hypertension (TROPHY):design and 2-year progress report, Hypertension,44 (2004) 125-126.
[67]X. Peng, Y. Li, J. Li, F.Y. Liu, Y.M. Peng, L. Sun, L.T. Zhou, W.B. Tang, Y.Y. He, X. Chen, L.J. Yang, J. Chen, J.W. Wu, J.D. Peng, D.J. Wang, R.H. Yu, [Metabolic syndrome and chronic kidney disease in a rural adult population of Hunan province, China], Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi,30 (2009) 1221-1225.
[68]李瑛,湖南省长沙县慢性肾脏病的流行病学研究,中华肾脏病杂志,(2010)123-127.
[69]K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification, American journal of kidney diseases:the official journal of the National Kidney Foundation,39 (2002) S1-266.
[70]Y.C. Ma, L. Zuo, J.H. Chen, Q. Luo, X.Q. Yu, Y. Li, J.S. Xu, S.M. Huang, L.N. Wang, W. Huang, M. Wang, GB. Xu, H.Y. Wang, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease, Journal of the American Society of Nephrology:JASN,17 (2006) 2937-2944.
[71]J. Coresh, E. Selvin, L.A. Stevens, J. Manzi, J.W. Kusek, P. Eggers, F. Van Lente, A.S. Levey, Prevalence of chronic kidney disease in the United States, JAMA: the journal of the American Medical Association,298 (2007) 2038-2047.
[72]S.J. Chadban, E.M. Briganti, P.G Kerr, D.W. Dunstan, T.A. Welborn, P.Z. Zimmet, R.C. Atkins, Prevalence of kidney damage in Australian adults:The AusDiab kidney study, Journal of the American Society of Nephrology:JASN, 14(2003)S131-138.
[73]D. Reyes, S.Q. Lew, P.L. Kimmel, Gender differences in hypertension and kidney disease, The Medical clinics of North America,89 (2005) 613-630.
[74]范文娟,新疆地区成年体检人群中慢性肾脏病患病率及相关危险因素调查,中华肾脏病杂志,27(2011)345-348.
[75]T.V. Perneger, F.J. Nieto, P.K. Whelton, M.J. Klag, G.W. Comstock, M. Szklo, A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study, JAMA:the journal of the American Medical Association,269 (1993) 488-493.
[76]M.V. Rao, Y. Qiu, C. Wang, G. Bakris, Hypertension and CKD:Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES),1999-2004, American journal of kidney diseases:the official journal of the National Kidney Foundation,51 (2008) S30-37.
[77]E. Pimenta, S. Oparil, Prehypertension:epidemiology, consequences and treatment, Nature reviews. Nephrology,6 (2010) 21-30.
[78]Y. Ishikawa, J. Ishikawa, S. Ishikawa, E. Kajii, J.E. Schwartz, T.G. Pickering, K. Kario, Prehypertension and the risk for cardiovascular disease in the Japanese general population:the Jichi Medical School Cohort Study, Journal of hypertension,28 (2010) 1630-1637.
[79]G Chen, X. Lai, Q. Jiang, F. Chen, N. Chen, H. Huang, J. Liang, L. Li, J. Wen, L. Lin, J. Yao, Cardiovascular disease (CVD) risk, insulin resistance and beta-cell function in prehypertension population of China, Atherosclerosis,217 (2011) 279-285.
[80]M.J. Kim, N.K. Lim, H.Y. Park, Relationship between prehypertension and chronic kidney disease in middle-aged people in Korea:the Korean genome and epidemiology study, BMC public health,12 (2012) 960.
[81]Y. Yano, S. Fujimoto, Y. Sato, T. Konta, K. Iseki, T. Moriyama, K. Yamagata, K. Tsuruya, H. Yoshida, K. Asahi, I. Kurahashi, Y. Ohashi, T. Watanabe, Association between prehypertension and chronic kidney disease in the Japanese general population, Kidney international,81 (2012) 293-299.
[82]D.D. Maki, J.Z. Ma, T.A. Louis, B.L. Kasiske, Long-term effects of antihypertensive agents on proteinuria and renal function, Archives of internal medicine,155 (1995) 1073-1080.
[83]J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, A.S. Levey, Prevalence of chronic kidney disease and decreased kidney function in the adult US population:Third National Health and Nutrition Examination Survey, American journal of kidney diseases:the official journal of the National Kidney Foundation,41 (2003) 1-12.
[84]C.M. Clase, A.X. Garg, B.A. Kiberd, Prevalence of low glomerular filtration rate in nondiabetic Americans:Third National Health and Nutrition Examination Survey (NHANES Ⅲ), Journal of the American Society of Nephrology:JASN, 13 (2002) 1338-1349.
[85]M. Kurella, J.C. Lo, GM. Chertow, Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults, Journal of the American Society of Nephrology:JASN,16 (2005) 2134-2140.
[86]N.L. Edwards, The role of hyperuricemia and gout in kidney and cardiovascular disease, Cleveland Clinic journal of medicine,75 Suppl 5 (2008) S13-16.
[87]R.S. Vasan, A. Beiser, S. Seshadri, M.G. Larson, W.B. Kannel, R.B. D'Agostino, D. Levy, Residual lifetime risk for developing hypertension in middle-aged women and men:The Framingham Heart Study, JAMA,287 (2002) 1003-1010.
[88]H. Tomiyama, C. Matsumoto, J. Yamada, M. Yoshida, M. Odaira, K. Shiina, M. Nagata, A. Yamashina, Predictors of progression from prehypertension to hypertension in Japanese men, Am J Hypertens,22 (2009) 630-636.
[89]S.A. Williams, E.L. Michelson, V.A. Cain, M. Yang, S.D. Nesbitt, B.M. Egan, S. Julius, An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY), J Clin Hypertens (Greenwich),10 (2008) 436-442.
[90]P.K. Li, B.C. Kwan, C.B. Leung, T.H. Kwan, K.M. Wong, S.L. Lui, W.K. Tsang, C.C. Mak, S.K. Mak, A.W. Yu, S. Tang, Prevalence of silent kidney disease in Hong Kong:the screening for Hong Kong Asymptomatic Renal Population and Evaluation (SHARE) program, Kidney Int Suppl, (2005) S36-40.
[91]陈.王.董.何.刘.骆.谭.林.聂.毛.陈.余学清,广州市城区普通人群中慢性肾脏病的流行病学研究,中华肾脏病杂志,(2007)68-74.
[92]刘.刘.胡.邢.施学忠,郑州市城区成年人慢性肾脏病流行病学调查,中华肾脏病杂志,(2008)355-359.
[93]N. Chen, W. Wang, Y. Huang, P. Shen, D. Pei, H. Yu, H. Shi, Q. Zhang, J. Xu, Y. Lv, Q. Fan, Community-based study on CKD subjects and the associated risk factors, Nephrology, dialysis, transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,24 (2009)2117-2123.
[94]K. Kario, J. Ishikawa, T.G Pickering, S. Hoshide, K. Eguchi, M. Morinari, Y. Hoshide, T. Kuroda, K. Shimada, Morning hypertension:the strongest independent risk factor for stroke in elderly hypertensive patients, Hypertension research:official journal of the Japanese Society of Hypertension,29 (2006) 581-587.
[95]R. Karasek, Job strain and the prevalence and outcome of coronary artery disease, Circulation,94 (1996) 1140-1141.
[96]S.D. Pierdomenico, D. Lapenna, A. Bucci, R. Di Tommaso, R. Di Mascio, B.M. Manente, M.P. Caldarella, M. Neri, F. Cuccurullo, A. Mezzetti, Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension, Am J Hypertens,18 (2005) 1422-1428.
[98 K. Bjorklund, L. Lind, B. Zethelius, B. Andren, H. Lithell, Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men, Circulation,107 (2003) 1297-1302.
[98]C. Selenta, B.E. Hogan, W. Linden, How often do office blood pressure measurements fail to identify true hypertension? An exploration of white-coat normotension, Archives of family medicine,9 (2000) 533-540.
[99]S.D. Pierdomenico, G. Pannarale, F. Rabbia, D. Lapenna, R. Licitra, M. Zito, M. Campanella, C. Gaudio, F. Veglio, F. Cuccurullo, Prognostic relevance of masked hypertension in subjects with prehypertension, Am J Hypertens,21 (2008) 879-883.
[100]R.H. Fagard, C. Van Den Broeke, P. De Cort, Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice, Journal of human hypertension,19 (2005) 801-807.
[101]T. Theorell, R.A. Karasek, Current issues relating to psychosocial job strain and cardiovascular disease research, J Occup Health Psychol,1 (1996) 9-26.
[102]G. Cesana, R. Sega, M. Ferrario, P. Chiodini, G Corrao, G. Mancia, Job strain and blood pressure in employed men and women:a pooled analysis of four northern italian population samples, Psychosom Med,65 (2003) 558-563.
[103]S. Uchiyama, T. Kurasawa, T. Sekizawa, H. Nakatsuka, Job strain and risk of cardiovascular events in treated hypertensive Japanese workers:hypertension follow-up group study, J Occup Health,47 (2005) 102-111.
[104]G. Cesana, M. Ferrario, R. Sega, C. Milesi, G. De Vito, G. Mancia, A. Zanchetti, Job strain and ambulatory blood pressure levels in a population-based employed sample of men from northern Italy, Scand J Work Environ Health,22 (1996) 294-305.
[105]S.W. Tobe, A. Kiss, S. Sainsbury, M. Jesin, R. Geerts, B. Baker, The impact of job strain and marital cohesion on ambulatory blood pressure during 1 year:the double exposure study, American journal of hypertension,20 (2007) 148-153.
[106]C. Brisson, N. Laflamme, J. Moisan, A. Milot, B. Masse, M. Vezina, Effect of family responsibilities and job strain on ambulatory blood pressure among white-collar women, Psychosom Med,61 (1999) 205-213.
[107]吴寿岭,张子强,宋胜斌,么太成,李云,王剑利,王娜,金成,李金锋,高血压前期人群血压转归及其影响因素,中华心血管病杂志,38(2010)145-152.
[108]E.R. Miller,3rd, T.P. Erlinger, D.R. Young, M. Jehn, J. Charleston, D. Rhodes, S.K. Wasan, L.J. Appel, Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT), Hypertension,40 (2002) 612-618.
[109]V.J. Stevens, E. Obarzanek, N.R. Cook, I.M. Lee, L.J. Appel, D. Smith West, N.C. Milas, M. Mattfeldt-Beman, L. Belden, C. Bragg, M. Millstone, J. Raczynski, A. Brewer, B. Singh, J. Cohen, Long-term weight loss and changes in blood pressure:results of the Trials of Hypertension Prevention, phase Ⅱ, Annals of internal medicine,134 (2001) 1-11.
[110]K.G. Alberti, P. Zimmet, J. Shaw, The metabolic syndrome--a new worldwide definition, Lancet,366 (2005) 1059-1062.
[111]P.J. Elmer, E. Obarzanek, W.M. Vollmer, D. Simons-Morton, V.J. Stevens, D.R. Young, P.H. Lin, C. Champagne, D.W. Harsha, L.P. Svetkey, J. Ard, P.J. Brantley, M.A. Proschan, T.P. Erlinger, L.J. Appel, Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial, Annals of internal medicine,144 (2006) 485-495.
[112]L.P. Svetkey, Management of prehypertension, Hypertension,45 (2005) 1056-1061.
[113]P. Varkey, A. Sathananthan, A. Scheifer, S. Bhagra, A. Fujiyoshi, A. Tom, M.H. Murad, Using quality-improvement techniques to enhance patient education and counselling of diagnosis and management, Quality in primary care,17 (2009) 205-213.
1 Pickering TG, Davidson K, Gerin W, et al. Masked hypertension[J]. Hypertension, 2002,40(6):795-796.
2. Pickering T. White coat hypertension'--should it be treated or not[J]? Cleveland Clinic journal of medicine.2002;69(8):584-585.
3. Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the Management of Arterial Hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. Journal of hypertension,2007, 25(6):1105-1187.
4. Cacciolati C, Hanon O, Alperovitch A, et al. Masked hypertension in the elderly: cross-sectional analysis of a population-based sample [J]. Am J Hypertens,2011, 24(6):674-680.
5. Hanninen MR, Niiranen TJ, Puukka PJ, et al. Determinants of masked hypertension in the general population:the Finn-Home study [J]. Journal of hypertension,2011,29(10):1880-1888.
6. Zhou J, Liu C, Shan P, et al. Prevalence and distinguishing features of masked hypertension in type 2 diabetic patients [J]. Journal of diabetes and its complications, 2013,27(1):82-86.
7. Baguet JP, Levy P, Barone-Rochette G, et al. Masked hypertension in obstructive sleep apnea syndrome [J]. Journal of hypertension,2008,26(5):885-892.
8. Sobrino J, Domenech M, Camafort M, et al. Prevalence of masked hypertension in a cohort of controlled hypertensive patients in Spain[J]. Med Clin, 2011,136(14):607-612.
9. Andrikou I, Tsioufis C, Dimitriadis K, et al. Similar levels of low-grade inflammation and arterial stiffness in masked and white-coat hypertension: comparisons with sustained hypertension and normotension[J]. Blood pressure monitoring,2011,16(5):218-223.
10. Andalib A, Akhtari S, Rigal R, et al. Determinants of masked hypertension in hypertensive patients treated in a primary care setting[J]. Internal medicine journal,2012,42(3):260-266.
11. Verberk WJ, Kessels AG, de Leeuw PW. Prevalence, causes, and consequences of masked hypertension:a meta-analysis[J]. American journal of hypertension,2008,21 (9):969-975.
12. Schultz MG, Hare JL, Marwick TH, et al. Masked hypertension is "unmasked" by low-intensity exercise blood pressure[J]. Blood pressure,2011,20(5):284-289.
13. Ostrow V, Wu S, Aguilar A, et al. Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents[J]. The Journal of pediatrics,2011,158(4):628-633.
14. Asayama K, Sato A, Ohkubo T, et al. The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome:the Ohasama study[J]. Hypertens Res,2009,32(6),438-443.
15. Kim SK, Bae JH, Nah DY, et al. Frequency and related factors of masked hypertension at a worksite in Korea[J]. Journal of preventive medicine and public health,2011,44(3):131-139.
16. Ogedegbe G, Pickering TG, Clemow L, et al. The misdiagnosis of hypertension: the role of patient anxiety[J]. Archives of internal medicine,2008,168(22): 2459-2465.
17. Uzu T, Nakao K, Kume S, et al. High sodium intake is associated with masked hypertension in Japanese patients with type 2 diabetes and treated hypertension[J]. American journal of hypertension,2012,25(11):1170-1174.
18. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring:executive summary:a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association[J]. Hypertension, 2008,52(1):1-9.
19. Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accuracy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension[J]. Hypertension research,2012,35(7):750-755.
20. Kawano Y, Horio T, Matayoshi T, et al. Masked hypertension:subtypes and target organ damage[J]. Clin Exp Hypertens,2008,30(3):289-296.
21. Cuspidi C, Negri F, Sala C, et al. Masked hypertension and echocardiographic left ventricular hypertrophy:an updated overview[J]. Blood pressure monitoring, 2012,17(1):8-13.
22. Takeno K, Mita T, Nakayama S, et al. Masked hypertension, endothelial dysfunction, and arterial stiffness in type 2 diabetes mellitus:a pilot study[J]. Am J Hypertens,2012,25(2):165-170.
23.傅坤发,胡建,何畏,等.隐性高血压患者内皮依赖性血管舒张功能的变化[J].中华高血压杂志,2010,18(03)：259-262.
24. Veerabhadrappa P, Diaz KM, Feairheller DL, et al. Endothelial-dependent flow-mediated dilation in African Americans with masked-hypertension[J]. American journal of hypertension,2011,24(10):1102-1107.
25. Hara A, Ohkubo T, Kondo T, et al. Detection of silent cerebrovascular lesions in individuals with 'masked' and 'white-coat' hypertension by home blood pressure measurement:the Ohasama study[J]. Journal of hypertension,2009,27(5):1049-1055.
26. Ishikawa J, Hoshide S, Eguchi K, et al. Masked hypertension defined by ambulatory blood pressure monitoring is associated with an increased serum glucose level and urinary albumin-creatinine ratio[J]. J Clin Hypertens,2010,12(8):578-587.
27. Bombelli M, Sega R, Facchetti R, et al. Prevalence and clinical significance of a greater ambulatory versus office blood pressure ('reversed white coat' condition) in a general population[J]. Journal of hypertension,2005,23(3):513-520.
28. Ormezzano O, Baguet JP, Francois P, et al. Is there any real target organ damage associated with white-coat normotension[J]? Clinical autonomic research,2004,14(3):160-166.
29. Yoon HJ, Ahn Y, Park JB, et al. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension [J]? Clin Exp Hypertens,2010,32(7):480-485.
30. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease[J]. Hypertension,2009,53(1):20-27.
31. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients[J]. JAMA,2004,291(11):1342-1349.
32. Pickering TG, White WB, Giles TD, et al. When and how to use self (home) and ambulatory blood pressure monitoring[J]. Journal of the American Society of Hypertension,2010,4(2):56-61.
33. Pickering TG Should doctors still measure blood pressure[J]? J Clin Hypertens, 2006,8(6):394-396.
34. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects:an updated meta analysis[J]. American journal of hypertension,2011,24(1):52-58.
35. Hanninen MR, Niiranen TJ, Puukka PJ, et al. Prognostic significance of masked and white-coat hypertension in the general population:the Finn-Home Study [J]. Journal of hypertension,2012,30(4):705-712.
36. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Engl J Med,2008,358(18):1887-1898.
37. Cushman WC, Davis BR, Pressel SL, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial[J]. J Clin Hypertens,2012,14(1):20-31.
38. Phillips RA. Controversies in blood pressure goal guidelines and masked hypertension[J]. Ann N Y Acad Sci,2012,1254(4):115-122.
39. Ohta Y, Tsuchihashi T, Kiyohara K. Consequence of masked hypertension in treated hypertensive outpatients:1-year follow-up study [J]. Clin Exp Hypertens,2011,33(4):270-274.
40. Drager LF, Pedrosa RP, Diniz PM, et al. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea[J]. Hypertension,2011,57(3):549-555.
41. Gu Q, Burt VL, Paulose-Ram R, et al. High blood pressure and cardiovascular disease mortality risk among U.S. adults:the third National Health and Nutrition Examination Survey mortality follow-up study [J]. Annals of epidemiology, 2008,18(4):302-309.
42. Furusawa EA, Filho UD, Junior DM, et al. Home and ambulatory blood pressure to identify white coat and masked hypertension in the pediatric patient[J]. Am J Hypertens,2011,24(8):893-897.
43. van der Wel MC, Buunk IE, van Weel C, et al. A novel approach to office blood pressure measurement:30-minute office blood pressure vs daytime ambulatory blood pressure[J]. Ann Fam Med,2011,9(2):128-135.
44. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass:the Masked Hypertension Study[J]. Am J Hypertens,2012,25(6):664-671.
45. Pickering TG. The natural history of hypertension:prehypertension or masked hypertension[J]? J Clin Hypertens,2007,9(10):807-810.
46. Enstrom IE, Pennert KM. Masked hypertension in untreated normotensives: difference between a work day and a leisure day[J]? Blood Press Monit,2011,16(1):7-10.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |